With a price-to-sales (or "P/S") ratio of 4x BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in the United States have P/S ratios greater than 12.4x and even P/S higher than 54x are not unusual. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so limited.
View our latest analysis for BioCryst Pharmaceuticals
NasdaqGS:BCRX Price to Sales Ratio vs Industry December 28th 2023
How BioCryst Pharmaceuticals Has Been Performing
Recent revenue growth for BioCryst Pharmaceuticals has been in line with the industry. Perhaps the market is expecting future revenue performance to dive, which has kept the P/S suppressed. If not, then existing shareholders have reason to be optimistic about the future direction of the share price.
If you'd like to see what analysts are forecasting going forward, you should check out our free report on BioCryst Pharmaceuticals.
Do Revenue Forecasts Match The Low P/S Ratio?
The only time you'd be truly comfortable seeing a P/S as depressed as BioCryst Pharmaceuticals' is when the company's growth is on track to lag the industry decidedly.
Retrospectively, the last year delivered an exceptional 33% gain to the company's top line. This great performance means it was also able to deliver immense revenue growth over the last three years. Therefore, it's fair to say the revenue growth recently has been superb for the company.
Turning to the outlook, the next three years should generate growth of 22% per annum as estimated by the eleven analysts watching the company. With the industry predicted to deliver 249% growth per year, the company is positioned for a weaker revenue result.
With this in consideration, its clear as to why BioCryst Pharmaceuticals' P/S is falling short industry peers. Apparently many shareholders weren't comfortable holding on while the company is potentially eyeing a less prosperous future.
The Bottom Line On BioCryst Pharmaceuticals' P/S
Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.
As we suspected, our examination of BioCryst Pharmaceuticals' analyst forecasts revealed that its inferior revenue outlook is contributing to its low P/S. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. It's hard to see the share price rising strongly in the near future under these circumstances.
Having said that, be aware BioCryst Pharmaceuticals is showing 2 warning signs in our investment analysis, and 1 of those can't be ignored.
It's important to make sure you look for a great company, not just the first idea you come across. So if growing profitability aligns with your idea of a great company, take a peek at this free list of interesting companies with strong recent earnings growth (and a low P/E).
Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
